2cureX AB
2QE
Company Profile
Business description
2cureX AB is a biotech company. The company is engaged in improving treatment efficiency, mainly for cancer patients. It is involved in developing a product, namely IndiTreat, which is a technology for the treatment of colorectal, ovarian, and pancreatic cancers. The company's sub-products include IndiTreat Test, IndiTreat clinical programs, and IndiTreat Therapy Design.
Contact
Fruebjergvej 3
CopenhagenDK-2100
DNKT: +45 22115399
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
14
Stocks News & Analysis
stocks
Expanding store network for ASX listed retailer
Sales growth but lack of margin expansion due to competition.
stocks
SpaceX jumps 19% in debut, but hurdles lie ahead
Pre-IPO holders could start selling later this summer, and earnings will be an important test.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,128.00 | 14.60 | 0.16% |
| CAC 40 | 8,406.66 | 55.79 | 0.67% |
| DAX 40 | 24,921.59 | 286.29 | 1.16% |
| Dow JONES (US) | 51,796.64 | 594.38 | 1.16% |
| FTSE 100 | 10,426.44 | 45.28 | -0.43% |
| HKSE | 24,842.67 | 124.57 | 0.50% |
| NASDAQ | 26,499.32 | 610.47 | 2.36% |
| Nikkei 225 | 69,317.50 | 3,297.46 | 4.99% |
| NZX 50 Index | 13,360.59 | 33.28 | -0.25% |
| S&P 500 | 7,541.74 | 110.28 | 1.48% |
| S&P/ASX 200 | 8,914.00 | 7.00 | 0.08% |
| SSE Composite Index | 4,096.47 | 64.96 | 1.61% |